Following considerable pressure over policies related to the accessibility of unpublished clinical trial data in its database and conflicts of interest for its officials (Hampton T. JAMA. 2011;306:593-595), the European Medicines Agency (EMA) is taking steps to increase transparency.
As a part of this effort, in July the EMA, the European counterpart to the US Food and Drug Administration (FDA), announced that it will release the agendas and minutes of its scientific committee meetings. “This latest initiative is an important part of opening up our operations, to reinforce the trust and reputation of the Agency as a public health body,” said Executive Director Guido Rasi, MD, in a press statement (http://tinyurl.com/bn4udam).
Hampton T. European Drug Agency Works to Improve Transparency, but Skepticism Remains. JAMA. 2012;308(9):850–851. doi:https://doi.org/10.1001/2012.jama.10451
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: